Corcept Therapeutics Inc
NovoCure Stock Rose after Positive Results from Clinical Trial
On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40.
Teva Sued by Corcept Therapeutics over Patent Infringement Claim
On March 15, 2018, Corcept Therapeutics announced that it had filed a lawsuit against Teva Pharmaceutical for the infringement of its Korlym patents.